InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a report released on Saturday. The brokerage issued a sell rating on the stock.

Separately, Lake Street Capital started coverage on InspireMD in a report on Wednesday, December 11th. They set a “buy” rating and a $5.00 price target for the company.

InspireMD Price Performance

Shares of InspireMD stock opened at $3.19 on Friday. The business has a fifty day simple moving average of $2.78 and a two-hundred day simple moving average of $2.74. InspireMD has a 1 year low of $1.81 and a 1 year high of $3.42. The company has a market capitalization of $83.21 million, a price-to-earnings ratio of -4.25 and a beta of 1.00.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in NSPR. Parkman Healthcare Partners LLC increased its position in InspireMD by 721.2% during the 4th quarter. Parkman Healthcare Partners LLC now owns 854,716 shares of the company’s stock worth $2,248,000 after buying an additional 750,635 shares during the period. Essex Investment Management Co. LLC bought a new position in shares of InspireMD in the fourth quarter worth $191,000. Northern Trust Corp increased its position in shares of InspireMD by 103.7% in the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock worth $126,000 after purchasing an additional 24,452 shares during the period. Schonfeld Strategic Advisors LLC increased its position in shares of InspireMD by 153.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock worth $79,000 after purchasing an additional 18,233 shares during the period. Finally, Legato Capital Management LLC bought a new position in shares of InspireMD in the fourth quarter worth $47,000. Institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.